Acorda Therapeutics Inc. (ACOR) and Insmed Incorporated (NASDAQ:INSM) Contrasting side by side

Acorda Therapeutics Inc. (NASDAQ:ACOR) and Insmed Incorporated (NASDAQ:INSM) compete against each other in the Biotechnology sector. We will contrast them and contrast their analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Acorda Therapeutics Inc. 409.40M 1.28 5.72M 0.71 20.63
Insmed Incorporated 31.74M 64.63 329.91M -4.22 0.00

Table 1 highlights Acorda Therapeutics Inc. and Insmed Incorporated’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 represents Acorda Therapeutics Inc. (NASDAQ:ACOR) and Insmed Incorporated (NASDAQ:INSM)’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
Acorda Therapeutics Inc. -1.40% 5.7% 2.7%
Insmed Incorporated -1,039.41% -99.4% -46.9%

Volatility and Risk

Acorda Therapeutics Inc. has a 1.47 beta, while its volatility is 47.00% which is more volatile than Standard & Poor’s 500. Insmed Incorporated has a 3.08 beta and it is 208.00% more volatile than Standard & Poor’s 500.

Liquidity

The Current Ratio and a Quick Ratio of Acorda Therapeutics Inc. are 3.8 and 3.6. Competitively, Insmed Incorporated has 6.5 and 6.4 for Current and Quick Ratio. Insmed Incorporated’s better ability to pay short and long-term obligations than Acorda Therapeutics Inc.

Analyst Recommendations

Acorda Therapeutics Inc. and Insmed Incorporated Recommendations and Ratings are available on the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Acorda Therapeutics Inc. 1 1 1 2.33
Insmed Incorporated 0 1 7 2.88

The consensus price target of Acorda Therapeutics Inc. is $21.5, with potential upside of 96.71%. Competitively Insmed Incorporated has an average price target of $40.43, with potential upside of 53.09%. The results provided earlier shows that Acorda Therapeutics Inc. appears more favorable than Insmed Incorporated, based on analyst belief.

Insider and Institutional Ownership

About 1.4% of Acorda Therapeutics Inc.’s share are owned by insiders. Competitively, insiders own roughly 1% of Insmed Incorporated’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Acorda Therapeutics Inc. 9.02% -12.03% -29.7% -48.85% -39.92% -6.1%
Insmed Incorporated 1.85% 22.42% 66.16% 37.84% 22.92% 126.83%

For the past year Acorda Therapeutics Inc. has -6.1% weaker performance while Insmed Incorporated has 126.83% stronger performance.

Summary

Acorda Therapeutics Inc. beats on 9 of the 13 factors Insmed Incorporated.

Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); Zanaflex capsules and tablets for the management of spasticity; and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops CVT-301 that has completed a Phase III clinical trial for the treatment of OFF periods in ParkinsonÂ’s disease; CVT-427, which has completed a Phase I clinical trial to treat migraine; Tozadenant that is in Phase III clinical trial for reduction of OFF time in ParkinsonÂ’s disease; SYN120, which is in Phase II clinical trial to treat ParkinsonÂ’s disease-related dementia; and BTT1023 (timolumab) that is in Phase II clinical trial for primary sclerosing cholangitis. Further, it develops rHIgM22, which is in Phase I clinical trial for the treatment of MS; Cimaglermin alfa that has completed a Phase I clinical trial in heart failure patients; and Chondroitinase Program that is in research stage for the treatment of spinal cord injury. The company has collaborations and license agreements with Biogen International GmbH; Alkermes plc; Rush-Presbyterian St. Luke's Medical Center; Alkermes, Inc.; SK Biopharmaceuticals Co., Ltd.; Astellas Pharma Europe Ltd.; Canadian Spinal Research Organization; Cambridge Enterprise Limited and King's College London; Mayo Foundation for Education and Research; Paion AG; Medarex, Inc.; and Brigham and WomenÂ’s Hospital, Inc. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.

Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with rare diseases. The companyÂ’s lead product candidate is ARIKAYCE or liposomal amikacin for inhalation, a formulation of amikacin that is in late-stage clinical development for adult patients with treatment refractory nontuberculous mycobacteria lung disease caused by Mycobacterium avium complex. It is also developing INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1, which has completed a Phase I clinical study for activating neutrophil serine proteases that are implicated in the pathology of chronic inflammatory lung diseases, such as non-cystic fibrosis bronchiectasis; and INS1009, an inhaled nanoparticle formulation of a treprostinil prodrug, which has completed a Phase I clinical study for treating rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1999 and is headquartered in Bridgewater, New Jersey.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.